相关实验视频

Updated: May 30, 2025

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

葡萄糖皮质体前给药改善了LNP-mRNA介导的蛋白质替代和基因组编辑疗法

Li Li¹, Mei Luo¹, Lifang Zhou¹

¹Laboratory of Biotherapy, National Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Renmin Nanlu 17, Chengdu 610041, Sichuan, China.

International journal of pharmaceutics

|January 29, 2025

概括

激活葡萄糖皮质体路径通过减少免疫细胞吸收来增强脂质纳米粒子 (LNP) 传递mRNA治疗药物. 这改善了目标细胞中的LNP积累,并提高了基因治疗的疗效.

科学领域:

生物技术是生物技术.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

脂质纳米颗粒 (LNP) 是基因治疗中mRNA输送的关键非病毒载体.
在体内输送LNP-mRNA面临生物障碍的挑战,限制治疗潜力.
优化LNP代谢对于有效的全身传递至关重要.

研究的目的:

通过调节内源代谢调节通路来增强体内LNP-mRNA的递送.
调查葡萄糖皮质体路径在LNP输送和细胞吸收中的作用.
评估葡萄糖皮质体激活对治疗结果的影响.

主要方法:

在临床前模型 (小鼠和非人类灵长类动物) 中激活葡萄糖皮质体路径.
量化LNP-mRNA系统传递和组织积累的量化.
评估血液循环和肝脏中的巨细胞化.
对蛋白质替代和CRISPR/Cas9基因编辑的治疗疗效的评估.

主要成果:

葡萄糖皮质体路径的激活增加了LNP-mRNA的系统性输送,增加了多达四倍.
这种增强与肝脏和血液中的巨细胞化减少有关.
在肝细胞,目标细胞中观察到LNP积累的增加.
基于LNP的蛋白质替代和基因组编辑的治疗疗效明显提高.

结论:

调节葡萄糖皮质体路径提供了一种实际的策略,以增强LNP-mRNA的全身传递.
抑制巨细胞化是改善LNP生物分布的关键机制.
这种方法有望优化基于RNA的治疗方法,包括基因编辑和蛋白质替代疗法.

关键词:

基因组编辑基因组编辑葡萄糖皮质类固醇是什么?脂质纳米颗粒的使用方法巨细胞是一个巨细胞.蛋白质替代剂是一种蛋白质替代剂.mRNA疗法是一种mRNA疗法.

更多相关视频

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...